Sanofi’s Toujeo has received
FDA recommendation for its expanded use in Type 1 Diabetes.
Toujeo is an insulin glargine
injection to control the highs and lows of blood sugar in the body. Indicated
to be used in adults and paediatric patients of age six and older.
Earlier, the injection was
considered suitable and approved only for patients age 18 and older. The
expanded approval came on the basis of successful results of the study EDITION
JUNIOR. It was the first randomized, controlled study which compared the
efficacy of Toujeo (insulin glargine 300 Units/mL) with Gla-100 (insulin
glargine 100 Units/mL). Toujeo was successful in lowering the blood sugar in
th...
